AAAmro Ali

Amro Ali

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amro Ali has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Indocyanine green-guided lymphadenectomy in gastrectomy for gastric cancer: a systematic review and meta-analysis with trial sequential analysis and meta-regression

    by Fatma A. Rikabe, Abdelrhman H. Mohamed, Amr Khalid Abdallah, Alyaa Ahmed Ibrahim, Asmaa Soliman, Marina Takawy, Nesreen Alhamwi, Mohamed Alatfawy, Ahmed Eldefrawy, Abdelrahman Abdalla Mohamed, et al.

    Background: Indocyanine green (ICG) near-infrared fluorescence is increasingly used to guide lymphadenectomy during laparoscopic gastrectomy for gastric cancer, but its impact on oncologic outcomes and perioperative safety compared with conventional surgery remains unclear. This systematic review and meta-analysis evaluates whether ICG guidance improves long-term outcomes and surgical quality in adults undergoing laparoscopic radical gastrectomy for resectable gastric adenocarcinoma. Methods: We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library through October 2025 for randomized trials and comparative cohort studies comparing ICG-guided lymphadenectomy with conventional laparoscopic gastrectomy without ICG. Random-effects models were used to pool effect estimates, with subgroup analyses, meta-regression, sensitivity analyses, and trial sequential analysis employed to explore heterogeneity and assess robustness. Results: From 1457 records, 28 studies were included, of which 25 contributed to the meta-analysis. ICG guidance significantly increased total lymph node retrieval [mean difference (MD): 6.57 nodes; 95% confidence interval (CI): 5.09–8.04; P < 0.0001] without increasing metastatic lymph node yield (MD: 0.01; 95% CI: −0.53 to 0.56; P = 0.958). No significant differences emerged in 5-year overall survival [risk ratio (RR): 0.99; 95% CI: 0.87–1.12], 2-year overall survival (RR: 1.03; 95% CI: 0.95–1.12), or 30-day mortality (RR: 1.19; 95% CI: 0.34–4.25). ICG-guided surgery showed modest reductions in operative time (MD: −8.67 min), blood loss (MD: −11.84 mL), and hospital stay (MD: −0.54 days), though heterogeneity was substantial for several perioperative outcomes. No significant reductions were seen in overall complications, Clavien–Dindo grade-specific complications, time to first flatus or oral intake or affected resection margins. Conclusion: ICG fluorescence–guided lymphadenectomy provides meaningful technical benefits during laparoscopic gastrectomy, increasing lymph node yield and modestly improving perioperative efficiency without compromising survival or increasing harm. These findings support ICG as a safe, effective adjunct to standard gastrectomy, though standardized protocols and further large, high-quality trials are needed to confirm long-term oncologic benefit.

  • Open Access

    Examining the link between tobacco use and gastric cancer mortality: A US population-based perspective (2003 to 2023)

    by Alyaa Ahmed Ibrahim, Mahmoud Tablawy, Mohammad Rayyan Mbbs Faisal, Ahmed Sami Fdle, Salma Ehab, Mahdi Ahmed, Sahil Mbbs Jairamani, Youmna Mahmoud Mostafa, Abdelrahman Aly Mohamed, Ehsanullah Alokozay, et al.

    Gastric cancer (GC) remains a major cause of cancer-related mortality worldwide, driven by multiple risk factors including infection, diet, genetics, and lifestyle behaviors. Tobacco use is a well-established modifiable risk factor that contributes to gastric carcinogenesis through chronic mucosal injury. This study aimed to evaluate long-term mortality trends of tobacco-associated GC among United States adults aged ≥ 25 years. We conducted a retrospective cross-sectional analysis using the CDC WONDER Multiple Cause of Death database from 2003 to 2023. Adults aged ≥ 25 years with GC (International Classification of Diseases, Tenth Revision: C16) and tobacco use disorder (International Classification of Diseases, Tenth Revision: F17) listed as underlying or contributing causes of death were included. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal trends were assessed using Joinpoint regression, reporting annual percent change and average annual percent change (AAPC). A total of 17,357 deaths were attributed to tobacco-associated GC (overall AAMR: 0.34). Mortality was higher among males (AAMR: 0.58) compared with females (AAMR: 0.15), with comparable temporal trends (AAPC: 4.59% vs 4.58%, respectively). Overall AAMR increased significantly from 0.15 in 2003 to 0.40 in 2023 (AAPC: 4.60%; 95% confidence interval: 3.11–6.18). Across racial groups, non-Hispanic (NH) Black individuals exhibited the highest mortality burden (AAMR: 0.56). However, NH White individuals demonstrated the steepest relative increase over time (AAPC: 3.89%). Regionally, the Midwest had the highest mortality burden (AAMR: 0.45) and the fastest growth (AAPC: 7.33%). Nonmetropolitan areas showed higher mortality (AAMR: 0.45) and a greater increase (AAPC: 4.73%) than metropolitan areas (AAMR: 0.33; AAPC: 4.14%). Tobacco-associated GC mortality has increased significantly in the United States from 2003 to 2023. While NH Black individuals bear the greatest overall mortality burden, NH White individuals exhibit the steepest rise in mortality rates. Higher burden and growth in the Midwest and rural areas highlight persistent geographic disparities.